<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433067</url>
  </required_header>
  <id_info>
    <org_study_id>UFranche-Comte</org_study_id>
    <nct_id>NCT02433067</nct_id>
  </id_info>
  <brief_title>Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer</brief_title>
  <acronym>CARDAPAC</acronym>
  <official_title>Impact of Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer, During Treatment With Trastuzumab in Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Franche-Comté</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Franche-Comté</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to examine the effects of 3 months of physical activity intervention&#xD;
      on myocardial function (Left ventricular ejection fraction) in patients with HER2+ breast&#xD;
      cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To evaluate in patients with HER2 + breast cancer, treated only by&#xD;
      trastuzumab, the impact of three months individualized physical activity intervention (55&#xD;
      minutes, 3 times per week) on left ventricular ejection fraction (LVEF).&#xD;
&#xD;
      Secondary objectives: To evaluate the impact of physical activity intervention on body&#xD;
      composition, muscle function, metabolic, hormonal and inflammatory responses, pain, fatigue&#xD;
      and quality of life.&#xD;
&#xD;
      This study examines patients aged 18 to 85 years, diagnosed with early breast cancer with&#xD;
      HER2 overexpression confirmed histologically and eligible to receive treatment with&#xD;
      trastuzumab (adjuvant).&#xD;
&#xD;
      This study includes 3 assessments phases: baseline (T0), 3 months (T3) and 6 months (T6) for&#xD;
      both arms.&#xD;
&#xD;
      The programme is organised as follows: Arm A &quot;standard oncologic care coupled with physical&#xD;
      activity intervention (3 times / week) &quot; for 3 months ; Arm B (control group) &quot;standard&#xD;
      oncologic care&quot;.&#xD;
&#xD;
      Between T3 and T6, volontary physical activity level will follow by actimetry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>The Left Ventricular Ejection Fraction (LVEF) will be evaluated baseline (T0), and 6 months (T6), to see if there is a significant change</time_frame>
    <description>evaluated with echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight and volume of left and right ventricular</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated byimpedance and with tape measure and pliers of Harpenden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic responses</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal voluntary quadriceps</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with chair quadriceps with strain gauge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score of Quality of life</measure>
    <time_frame>Baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score of Pain</measure>
    <time_frame>Baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of physical activity</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function (at rest and during exercise)</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with respiratory functional test and maximal exercise test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormonal responses</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory responses</measure>
    <time_frame>baseline (T0), 3 months (T3) and 6 months (T6)</time_frame>
    <description>evaluated with enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Physical activity intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Arm A &quot;standard oncologic care coupled with physical activity intervention (3 times / week) &quot; during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- Arm B (control group) &quot;standard oncologic care&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical activity intervention</intervention_name>
    <description>Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.</description>
    <arm_group_label>Physical activity intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>standard oncologic care</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 to 85 years&#xD;
&#xD;
          -  First breast cancer HER2 + histologically confirmed,&#xD;
&#xD;
          -  WHO grade Performance Index ≤1&#xD;
&#xD;
          -  Normal renal function (creatinine clearance ≥ 60 ml min-1)&#xD;
&#xD;
          -  Normal heart function with LVEF ≥ 50%&#xD;
&#xD;
          -  Normal liver function (AST and ALT normal)&#xD;
&#xD;
          -  Physical activity certificate issued by a cardiologist or an oncologist,&#xD;
&#xD;
          -  Active contraception or postmenopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients aged under 18 and over 85&#xD;
&#xD;
          -  Patients having no breast cancer HER2+&#xD;
&#xD;
          -  Patients with metastases&#xD;
&#xD;
          -  Heart failure (LVEF ≤50%) and respiratory (O2 saturation ≤ 92%),&#xD;
&#xD;
          -  Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis)&#xD;
&#xD;
          -  Symptomatic osteoarthritis,&#xD;
&#xD;
          -  Cardiovascular diseases (angina or uncontrolled high blood pressure) or heart-lung&#xD;
             (chronic obstructive pulmonary disease)&#xD;
&#xD;
          -  Patients suffering from malnutrition (Body Mass Index (BMI) &lt;18 kg m-2) or weight loss&#xD;
             of over 10% during the last 3 months,&#xD;
&#xD;
          -  Patients with psychiatric or cognitive disorders deemed unsuitable for a sporting&#xD;
             activity&#xD;
&#xD;
          -  Pregnant or lactating Patients.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Meneveau</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Franche-Comté</investigator_affiliation>
    <investigator_full_name>Fabienne Mougin-Guillaume</investigator_full_name>
    <investigator_title>Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

